FIELD: pharmacology.
SUBSTANCE: invention relates to indazole-3-carboxamides or pharmaceutically acceptable salts thereof, with formula 
I, where the radicals and symbols have meanings indicated in the claims. These compounds are inhibitors of the Wnt/β-catenin signalling pathway and can be used for treatment of various diseases and pathologies. This invention also relates to application of formula I compounds, or its analogues for treatment of diseases characterized by Wnt signalling pathway activation, such as, e.g., malignant neoplasm, abnormal cell proliferation, angiogenesis and osteoarthritis, for modulating cellular processes mediated by Wnt signalling pathway activation, as well as treatment of genetic diseases and neurological conditions/disorders/diseases caused by mutation or dysregulation of Wnt pathway activation and/or one or more components of the Wnt signalling pathway activation. Methods for treatment of WNT-related disease states are also proposed.
EFFECT: increased efficiency of compounds application.
42 cl, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDAZOLIE WNT SIGNAL PATHWAY INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | 2017 |
|
RU2682245C1 |
| INDASOLE INHIBITORS OF Wnt SIGNAL PATH AND THEIR THERAPEUTIC APPLICATIONS | 2013 |
|
RU2638932C2 |
| METHODS FOR USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF WNT/B-CATENIN SIGNAL PATH | 2017 |
|
RU2770613C2 |
| 1H-PYRAZOLO[3,4-B]PYRIDINES AND THEIR THERAPEUTIC APPLICATIONS | 2013 |
|
RU2689141C2 |
| 5-SUBSTITUTED INDAZOLE AS KINASE INHIBITORS | 2008 |
|
RU2487873C2 |
| GAMMA-DIKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS | 2014 |
|
RU2680716C2 |
| METHODS FOR PRODUCING CERTAIN 2-(PYRIDINE-3-YL)THIAZOLES | 2013 |
|
RU2647853C2 |
| 6-5 CONDENSED RINGS AS C5a INHIBITORS | 2018 |
|
RU2780338C2 |
| COMPOUNDS FOR THE TREATMENT OF CERTAIN LEUKOSIS | 2019 |
|
RU2804709C2 |
| SUBSTITUTED CHROMANS | 2015 |
|
RU2718060C2 |
